Humedix Co Ltd
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to H… Read more
Humedix Co Ltd - Asset Resilience Ratio
Humedix Co Ltd (200670) has an Asset Resilience Ratio of 20.79% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Humedix Co Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Humedix Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩60.00 Billion | 20.79% |
| Total Liquid Assets | ₩60.00 Billion | 20.79% |
Asset Resilience Insights
- Good Liquidity Position: Humedix Co Ltd maintains a healthy 20.79% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Humedix Co Ltd Industry Peers by Asset Resilience Ratio
Compare Humedix Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Humedix Co Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Humedix Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 31.56% | ₩78.82 Billion | ₩249.75 Billion | +4.28pp |
| 2023-12-31 | 27.28% | ₩60.00 Billion | ₩219.98 Billion | -7.95pp |
| 2022-12-31 | 35.23% | ₩80.01 Billion | ₩227.14 Billion | +10.05pp |
| 2021-12-31 | 25.18% | ₩54.35 Billion | ₩215.86 Billion | +0.33pp |
| 2020-12-31 | 24.85% | ₩43.66 Billion | ₩175.65 Billion | +10.84pp |
| 2019-12-31 | 14.02% | ₩19.41 Billion | ₩138.42 Billion | -9.32pp |
| 2018-12-31 | 23.34% | ₩29.94 Billion | ₩128.28 Billion | -6.00pp |
| 2017-12-31 | 29.34% | ₩38.06 Billion | ₩129.74 Billion | -16.31pp |
| 2016-12-31 | 45.64% | ₩59.86 Billion | ₩131.16 Billion | +45.42pp |
| 2015-12-31 | 0.22% | ₩252.88 Million | ₩115.90 Billion | -- |